Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Abstract Background Real-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in hormone receptor positive and human epidermal growth factor 2 receptor negative (HR+/HER2-) metastatic breast cancer (MBC) patients treated w...

Full description

Bibliographic Details
Main Authors: Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Metastatic breast cancer
CDK4/6 inhibitor
Endocrine therapy
Real-world
Online Access:https://doi.org/10.1186/s12885-023-10568-0

Internet

https://doi.org/10.1186/s12885-023-10568-0

Similar Items